Stomach cancer. clinical significance of the expression of key components of pd-1/pd-l1 immune checkpoint

被引：0
|
作者：
Kovaleva, Olga V. [1 ]
Podlesnaya, Polina A. [1 ]
Gratchev, Alexei N. [1 ]
Chang, Victor L. [2 ]
Ognerubov, Nikolai A. [2 ,3 ]
Kushlinskii, Nikolai E. [1 ]
机构：
[1] Blokhin National Medical Research Center of Oncology, Moscow, Russia
[2] Derzhavin Tambov State University, Tambov, Russia
[3] Tambov Regional Oncological Clinical Dispensary, Tambov, Russia
来源：
Journal of Nonlinear and Variational Analysis | 2021年 / 5卷 / 03期
关键词：
59;
D O I：
10.26442/18151434.2021.1.200749
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：122 / 127
相关论文
共 50 条
  • [31] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [32] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [33] PD-1 AND PD-L1 EXPRESSION IN OVARIAN CANCER
    Wieser, V.
    Gaugg, I.
    Fleischer, M.
    Fiegl, H.
    Marth, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 64 - 64
  • [34] PD-1 and PD-L1 expression in ovarian cancer
    Wieser, V.
    Gaugg, I.
    Fleischer, M.
    Reimer, D.
    Zeimet, A.
    Fiegl, H.
    Marth, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] Cancer cell expression of CCR2 regulates the PD-L1/PD-1 immune checkpoint in breast cancer
    Fein, Miriam R.
    Almeida, Ana S.
    Eberhardt, Anais
    Egeblad, Mikala
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [36] Progress in understanding the regulatory mechanisms of immune checkpoint proteins PD-1 and PD-L1 expression
    Wu, Xuanxuan
    Zhu, Zengjun
    Zhang, Jian
    Tian, Maojin
    Zhao, Peiqing
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [37] Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone Tumors
    N. E. Kushlinskii
    A. A. Alferov
    Yu. S. Timofeev
    E. S. Gershtein
    I. V. Bulycheva
    A. V. Bondarev
    M. Yu. Shchupak
    N. Yu. Sokolov
    S. B. Polikarpova
    M. M. Efimova
    A. A. Dzampaev
    E. A. Sushentsov
    M. D. Aliev
    E. R. Musaev
    Bulletin of Experimental Biology and Medicine, 2020, 170 : 64 - 68
  • [38] Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone Tumors
    Kushlinskii, N. E.
    Alferov, A. A.
    Timofeev, Yu. S.
    Gershtein, E. S.
    Bulycheva, I. V.
    Bondarev, A. V.
    Shchupak, M. Yu.
    Sokolov, N. Yu.
    Polikarpova, S. B.
    Efimova, M. M.
    Dzampaev, A. A.
    Sushentsov, E. A.
    Aliev, M. D.
    Musaev, E. R.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 170 (01) : 64 - 68
  • [39] PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
    Yang, Tianrui
    Kong, Ziren
    Ma, Wenbin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (02) : 546 - 553
  • [40] Expression patterns of PD-L1 and other immune checkpoint molecules in gastric cancer.
    Nakamura, Kenichi
    Hatakeyama, Keiichi
    Toriumi, Tetsuro
    Koseki, Yusuke
    Waki, Yuhei
    Fujiya, Keiichi
    Kamiya, Satoshi
    Makuuchi, Rie
    Tanizawa, Yutaka
    Bando, Etsuro
    Kawamura, Taiichi
    Yamaguchi, Ken
    Terashima, Masanori
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345